BRPI0413670A - composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso - Google Patents

composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso

Info

Publication number
BRPI0413670A
BRPI0413670A BRPI0413670-5A BRPI0413670A BRPI0413670A BR PI0413670 A BRPI0413670 A BR PI0413670A BR PI0413670 A BRPI0413670 A BR PI0413670A BR PI0413670 A BRPI0413670 A BR PI0413670A
Authority
BR
Brazil
Prior art keywords
obesity
treatment
facilitate
weight loss
pharmaceutical composition
Prior art date
Application number
BRPI0413670-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Jotham Wadsworth Coe
Brian Thomas O'neill
Steven Bradley Sands
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413670A publication Critical patent/BRPI0413670A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0413670-5A 2003-08-22 2004-08-09 composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso BRPI0413670A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49735303P 2003-08-22 2003-08-22
PCT/IB2004/002604 WO2005018622A1 (en) 2003-08-22 2004-08-09 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Publications (1)

Publication Number Publication Date
BRPI0413670A true BRPI0413670A (pt) 2006-10-24

Family

ID=34216115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413670-5A BRPI0413670A (pt) 2003-08-22 2004-08-09 composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso

Country Status (7)

Country Link
US (1) US20050043406A1 (enExample)
EP (1) EP1658059A1 (enExample)
JP (1) JP2007503384A (enExample)
BR (1) BRPI0413670A (enExample)
CA (1) CA2534271A1 (enExample)
MX (1) MXPA06002049A (enExample)
WO (1) WO2005018622A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
MXPA06003381A (es) * 2003-09-25 2006-06-08 Warner Lambert Co Beta aminoacidos terapeuticos.
AU2004276072A1 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Amino acids with affinity for the alpha2delta-protein
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands

Also Published As

Publication number Publication date
EP1658059A1 (en) 2006-05-24
MXPA06002049A (es) 2006-05-19
CA2534271A1 (en) 2005-03-03
JP2007503384A (ja) 2007-02-22
WO2005018622A8 (en) 2005-04-28
WO2005018622A1 (en) 2005-03-03
US20050043406A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
GEP20074197B (en) 5ht2c receptor modulators
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
TW200510429A (en) Heterocyclic MCHR1 antagonists
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BRPI0417156A (pt) composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
IL180603A (en) 3,4-Dihydro-1 H- Naphthalanones which are glucocorticoid receptor modulators
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
ATE517882T1 (de) Chinolinderivate
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
TW200806311A (en) Neuropeptide-2 receptor-agonists
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
BRPI0411585A (pt) compostos, composição farmacêutica e método de aglutinar receptores opióides em um paciente com necessidade dos mesmos
BR0317487A (pt) O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
TW200716134A (en) Tricyclic opioid modulators
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
TW200626158A (en) Naphthaline derivatives
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
BRPI0413670A (pt) composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.